

Atty. Dkt. No. 038602-1246

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Joseph SCHLESSINGER et al.
Title: NOVEL RECEPTOR-TYPE PHOSPHOTYROSINE PHOSPHATASE-KAPPA ANTIBODIES
Appl. No.: 09/887,669
Filing Date: October 1, 2001
Examiner: Michael T. Brannock
Art Unit: 1646

AMENDMENT TRANSMITTAL

Commissioner for Patents
Box NON-FEE AMENDMENT
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application. The following documents are enclosed:

- Amendment in Response to Notice under 37 CFR §§1.821-825 (10 pp.);
- Return copy of Notice to Comply (1 p.);
- Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821-825 (1 p.);
- 1 diskette containing CRF of sequence listing; and
- Paper copy of sequence listing (32 pp.).

[X] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Date 4/4/03

FOLEY & LARDNER
Customer Number: 22428




22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5475


Facsimile: (202) 672-5399

Respectfully submitted,

By 

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

RECEIVED
APR 09 2003
TECH CENTER 1600/2900



Atty. Dkt. No. 038602-1246

4A
JP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Joseph Schlessinger *et al.*

Title: Novel Receptor-Type Phosphotyrosine Phosphatase-Kappa Antibodies

Appl. No. 09/887,669

Filing Date: October 1, 2001

Examiner: Michael T. Brannock

Art Unit: 1646

RECEIVED
APR 09 2003
TECH CENTER 1600/2333

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed March 10, 2003, please amend the application as follows:

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 11, lines 24-34, and replace it with the following paragraph:

FIG. 3 shows the predicted amino acid sequence (SEQ ID NO: 1) of the RPTP_K precursor protein. The putative signal peptide and transmembrane (TM) segment are underlined. The two tandem phosphatase domains are boxed (PTP-1, PTP-2). The proteolytic cleavage site (RTKR, residues 640-643 of SEQ ID NO: 1) is printed in bold, and the Ig-like domain (Ig, 214-270) shown in bold italic